Presentation is loading. Please wait.

Presentation is loading. Please wait.

PRACTICAL RECOMMENDATIONS ON ANTI- THROMBOTIC TREATMENT IN PATIENTS TREATED WITH DRUG-ELUTING STENTS Giuseppe Biondi-Zoccai Ospedale S. Giovanni Battista.

Published byClaude Todd Modified over 8 years ago

Similar presentations

Presentation on theme: "PRACTICAL RECOMMENDATIONS ON ANTI- THROMBOTIC TREATMENT IN PATIENTS TREATED WITH DRUG-ELUTING STENTS Giuseppe Biondi-Zoccai Ospedale S. Giovanni Battista."— Presentation transcript:

1 PRACTICAL RECOMMENDATIONS ON ANTI- THROMBOTIC TREATMENT IN PATIENTS TREATED WITH DRUG-ELUTING STENTS Giuseppe Biondi-Zoccai Ospedale S. Giovanni Battista “Molinette” Università di Torino Convegno Regionale Piemonte e Valle d’Aosta “La morte improvvisa dal neonato all’adulto: un evento sempre inevitabile?” - Torino, 28-29 Settembre 2007 (h14.45-15.00)

2 Learning objectives I.Goals of antithrombotic treatment in patients undergoing drug-eluting stenting (DES) II.Pathophysiologic and clinical data on thrombotic risk in patients with DES III.Practical recommendations

3 Learning objectives I.Goals of antithrombotic treatment in patients undergoing drug-eluting stenting (DES) II.Pathophysiologic and clinical data on thrombotic risk in patients with DES III.Practical recommendations

4 Learning objectives I.Goals of antithrombotic treatment in patients undergoing drug-eluting stenting (DES) II.Clinical data on thrombotic risk in patients with DES III.Practical recommendations

5 Benefits of prolonged dual antiplatelet treatement Eisenstein et al, JAMA 2006 1501 patients treated with DES: no data on stent thrombosis (ST)

6 Incidence and predictors of stent thrombosis in DES Iakovou et al, JAMA 2006 2229 patients treated with DES: 0.6% subacute ST; 0.7% late ST; 1.3% total ST at 9 months !!!

7 Is dual antiplatelet therapy truly beneficial beyond 6 months? Airoldi et al, Circulation 2007 3021 patients treated with DES: 1.4% ST <6 months; 0.5% ST 6-18 months ; 1.9% total ST at 18 months

8 Learning objectives I.Goals of antithrombotic treatment in patients undergoing drug-eluting stenting (DES) II.Pathophysiologic and clinical data on thrombotic risk in patients with DES III.Practical recommendations

9 Resources for practical recommendations I.Grines CL, Bonow RO, Casey DE Jr, et al; American Heart Association; American College of Cardiology; Society for Cardiovascular Angiography and Interventions; American College of Surgeons; American Dental Association; American College of Physicians. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. Circulation. 2007 Feb 13;115(6):813-8. II.Hodgson JM, Stone GW, Lincoff AM, et al; Society for Cardiovascular Angiography and Interventions. Late stent thrombosis: considerations and practical advice for the use of drug- eluting stents: a report from the Society for Cardiovascular Angiography and Interventions Drug-eluting Stent Task Force. Catheter Cardiovasc Interv. 2007 Feb 15;69(3):327-33. III.Silber S, Albertsson P, Aviles FF, et al; Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart J. 2005 Apr;26(8):804-47. IV.Steinhubl SR, Berger PB, Mann JT 3rd, et al; CREDO Investigators. Clopidogrel for the Reduction of Events During Observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002 Nov 20;288(19):2411-20.

10 Resources for practical recommendations I.Grines CL, Bonow RO, Casey DE Jr, et al; American Heart Association; American College of Cardiology; Society for Cardiovascular Angiography and Interventions; American College of Surgeons; American Dental Association; American College of Physicians. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. Circulation. 2007 Feb 13;115(6):813-8. II.Hodgson JM, Stone GW, Lincoff AM, et al; Society for Cardiovascular Angiography and Interventions. Late stent thrombosis: considerations and practical advice for the use of drug- eluting stents: a report from the Society for Cardiovascular Angiography and Interventions Drug-eluting Stent Task Force. Catheter Cardiovasc Interv. 2007 Feb 15;69(3):327-33. III.Silber S, Albertsson P, Aviles FF, et al; Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart J. 2005 Apr;26(8):804-47. IV.Steinhubl SR, Berger PB, Mann JT 3rd, et al; CREDO Investigators. Clopidogrel for the Reduction of Events During Observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002 Nov 20;288(19):2411-20. 12m of ASA+TNP 12m of ASA+TNP 6-12m of ASA+TNP 12m of ASA+TNP ASA=aspirin; TNP=thienopyridine (clopidogrel or ticlopidine)

11 66-y-o woman with effort angina PTCA with non-overlapping bare- metal stents in right coronary artery

12 Optimal antithrombotic Rx? Life-long aspirin Life-long aspirin, TNP for 1 month Life-long aspirin, TNP for >6-12 months Life-long aspirin, TNP for 12-18 months TNP=thienopyridine (clopidogrel or ticlopidine)

13 Optimal antithrombotic Rx? Life-long aspirin Life-long aspirin, TNP for 1 month Life-long aspirin, TNP for >6-12 months Life-long aspirin, TNP for 12-18 months TNP=thienopyridine (clopidogrel or ticlopidine)

14 58-y-o man with silent ischemia PTCA with multiple small diameter paclitaxel-eluting stents in distal right coronary branches

15 Optimal antithrombotic Rx? Life-long aspirin Life-long aspirin, TNP for 1 month Life-long aspirin, TNP for >6-12 months Life-long aspirin, TNP for 12-18 months TNP=thienopyridine (clopidogrel or ticlopidine)

16 Optimal antithrombotic Rx? Life-long aspirin Life-long aspirin, TNP for 1 month Life-long aspirin, TNP for >6-12 months Life-long aspirin, TNP for 12-18 months TNP=thienopyridine (clopidogrel or ticlopidine)

17 71-y-o woman with unstable angina PTCA with sirolimus-eluting stents in unprotected distal left main and proximal left anterior descending

18 Optimal antithrombotic Rx? Life-long aspirin Life-long aspirin, TNP for 1 month Life-long aspirin, TNP for >6-12 months Life-long aspirin, TNP for 12-18 months TNP=thienopyridine (clopidogrel or ticlopidine)

19 Optimal antithrombotic Rx? Life-long aspirin Life-long aspirin, TNP for 1 month Life-long aspirin, TNP for >6-12 months Life-long aspirin, TNP for 12-18 months TNP=thienopyridine (clopidogrel or ticlopidine)

20 56-y-o man with de novo ST- elevation myocardial infarction PTCA with bare-metal stent in mid left anterior descending

21 Optimal antithrombotic Rx? Life-long aspirin Life-long aspirin, TNP for 1 month Life-long aspirin, TNP for >6-12 months Life-long aspirin, TNP for 12-18 months TNP=thienopyridine (clopidogrel or ticlopidine)

22 Optimal antithrombotic Rx? Life-long aspirin Life-long aspirin, TNP for 1 month Life-long aspirin, TNP for >6-12 months Life-long aspirin, TNP for 12-18 months TNP=thienopyridine (clopidogrel or ticlopidine)

23 Take home messages

24 1. Not all patients are born equal

25 2. Both accurate choice of revascularization strategy (CABG, PCI with BMS, PCI with DES, or none) AND aggressive medical RX are pivotal

26 3. Avoid aggressive and long-term dual antiplatelet therapy for all patients, as every single one should be handled differently All from All different

27 More humbly… DIAGNOSISPCITHERAPY CSA -Life-long aspirin POBALife-long aspirin BMSLife-long aspirin, TNP for 1 month DESLife-long aspirin, TNP for >6-12 months NSTEACS -Life-long aspirin, TNP for 12-18 months POBALife-long aspirin, TNP for 12-18 months BMSLife-long aspirin, TNP for 12-18 months DESLife-long aspirin, TNP for 12-18 months STEMI -Life-long aspirin, TNP for 1 month POBALife-long aspirin, TNP for 1 month BMSLife-long aspirin, TNP for 1 month DESLife-long aspirin, TNP for >6-12 months BMS=bare-metal stent; CSA=chronic stable angina; DES=drug-eluting stent; NSTEACS=non-ST-elevation acute coronary syndromes; PCI=percutaneous coronary intervention; POBA=pure-only balloon angioplasty; STEMI=ST-elevation myocardial infarction; TNP=thienopyridine (clopidogrel or ticlopidine)

28 For further slides on these topics please feel free to visit the metcardio.org website: http://www.metcardio.org/slides.html http://www.metcardio.org/slides.html

Download ppt "PRACTICAL RECOMMENDATIONS ON ANTI- THROMBOTIC TREATMENT IN PATIENTS TREATED WITH DRUG-ELUTING STENTS Giuseppe Biondi-Zoccai Ospedale S. Giovanni Battista."

Similar presentations

STENT THROMBOSIS: WHICH IMPACT IN REAL CLINICAL PRACTICE? Giuseppe Biondi Zoccai Divisione di Cardiologia, Università di Torino Ospedale S. Giovanni Battista.

STENT THROMBOSIS: WHICH IMPACT IN REAL CLINICAL PRACTICE? Giuseppe Biondi Zoccai Divisione di Cardiologia, Università di Torino Ospedale S. Giovanni Battista.
Cardiology Morning Report: Revascularization in Stable Ischemic Heart Disease Bobby Mathew, MD LSU Internal Medicine, HO-II.

Cardiology Morning Report: Revascularization in Stable Ischemic Heart Disease Bobby Mathew, MD LSU Internal Medicine, HO-II.
Gregg W. Stone MD for the ACUITY Investigators Gregg W. Stone MD for the ACUITY Investigators A Prospective, Randomized Trial of Bivalirudin in Acute Coronary.

Gregg W. Stone MD for the ACUITY Investigators Gregg W. Stone MD for the ACUITY Investigators A Prospective, Randomized Trial of Bivalirudin in Acute Coronary.
Can we prevent stent restenosis after coronary stent implantation

Can we prevent stent restenosis after coronary stent implantation
Asymptomatic Carotid Surgery Trial ACST-2 Collaborators Meeting 2014 Pembroke College, Oxford Is recent coronary stenting a problem (or an opportunity)

Asymptomatic Carotid Surgery Trial ACST-2 Collaborators Meeting 2014 Pembroke College, Oxford Is recent coronary stenting a problem (or an opportunity)
Basel Stent Cost-effectiveness Trial-Late Thrombotic Events (BASKET LATE) Trial Basel Stent Cost-effectiveness Trial-Late Thrombotic Events (BASKET LATE)

Basel Stent Cost-effectiveness Trial-Late Thrombotic Events (BASKET LATE) Trial Basel Stent Cost-effectiveness Trial-Late Thrombotic Events (BASKET LATE)
Drug-Eluting Stent Mortality Meta-Analysis Presented at European Society of Cardiology Scientific Congress, September 2006 Presented by Dr. Alain J. Nordmann.

Drug-Eluting Stent Mortality Meta-Analysis Presented at European Society of Cardiology Scientific Congress, September 2006 Presented by Dr. Alain J. Nordmann.
Call for CASES Leszek D. Stachaczyk, MD Pawel Buszman, MD, FESC, FSCAI American Heart of Poland, Ustroñ, Poland & CCU, Upper-Silesian Center of Cardiology,

Call for CASES Leszek D. Stachaczyk, MD Pawel Buszman, MD, FESC, FSCAI American Heart of Poland, Ustroñ, Poland & CCU, Upper-Silesian Center of Cardiology,
Ten Points to Remember from the 2007 STEMI Guideline Update Based on the 2007 Focused Update of the 2004 Guidelines for the Management of Patients With.

Ten Points to Remember from the 2007 STEMI Guideline Update Based on the 2007 Focused Update of the 2004 Guidelines for the Management of Patients With.
SCAAR UCR SWEDEN 2007 Stefan James, Jörg Carlsson, Johan Lindbäck, Tage Nilsson, Ulf Stenestrand, Lars Wallentin and Bo Lagerqvist for the SCAAR study.

SCAAR UCR SWEDEN 2007 Stefan James, Jörg Carlsson, Johan Lindbäck, Tage Nilsson, Ulf Stenestrand, Lars Wallentin and Bo Lagerqvist for the SCAAR study.
ACUTE CORONARY SYNDROMES:

ACUTE CORONARY SYNDROMES:
Coronary Stenting: Drug-eluting vs Bare-metal Natalie Cleaver, PA-S Lock Haven University PA Program Evidence Based Medicine February 26, 2009.

Coronary Stenting: Drug-eluting vs Bare-metal Natalie Cleaver, PA-S Lock Haven University PA Program Evidence Based Medicine February 26, 2009.
RITA-3 Is this a benign lesion in a benign condition? Who Needs Angioplasty in 2008? Stable Angina Stable Angina Keith A A Fox Professor of Cardiology.

RITA-3 Is this a benign lesion in a benign condition? Who Needs Angioplasty in 2008? Stable Angina Stable Angina Keith A A Fox Professor of Cardiology.
Applications of bivalirudin in interventional cardiology

Applications of bivalirudin in interventional cardiology
1 SIROLIMUS-ELUTING STENTS FOR IN-STENT RESTENOSIS TREATMENT IN 278 UNSELECTED PATIENTS: INSIGHTS ON LONG-TERM OUTCOMES FROM A LARGE TWO-CENTER REGISTRY.

1 SIROLIMUS-ELUTING STENTS FOR IN-STENT RESTENOSIS TREATMENT IN 278 UNSELECTED PATIENTS: INSIGHTS ON LONG-TERM OUTCOMES FROM A LARGE TWO-CENTER REGISTRY.
ARMYDA-4 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study Prospective, multicenter, randomized, double blind trial investigating.

ARMYDA-4 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study Prospective, multicenter, randomized, double blind trial investigating.
Richard Melsheimer Director, Medical Affairs Europe Centocor Eli Lilly and Company Coordinated Use of ReoPro and Drug Eluting Stents: Rationale and Evidence.

Richard Melsheimer Director, Medical Affairs Europe Centocor Eli Lilly and Company Coordinated Use of ReoPro and Drug Eluting Stents: Rationale and Evidence.
Treatment of In-Stent Restenosis by Paclitaxel Coated PTCA Balloons Presented at The American Heart Association Scientific Session 2006 Presented by Dr.

Treatment of In-Stent Restenosis by Paclitaxel Coated PTCA Balloons Presented at The American Heart Association Scientific Session 2006 Presented by Dr.
PRODIGY Objective Study Design Primary Composite Endpoint

PRODIGY Objective Study Design Primary Composite Endpoint
MANAGING ATHERO- THROMBOTIC RISK Early impact and long-term benefit of antiplatelet therapy What is the optimal duration of antiplatelet therapy? Giuseppe.

MANAGING ATHERO- THROMBOTIC RISK Early impact and long-term benefit of antiplatelet therapy What is the optimal duration of antiplatelet therapy? Giuseppe.

Similar presentations

Ads by Google